ArticleNuclear medicine communications2026
Evolutionary landscape and collaborative networks of global theranostic research in nuclear medicine: a visual bibliometric analysis.
Article in Nuclear medicine communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTheranostics, integrating diagnostic imaging with targeted radionuclide therapy, has become central to nuclear medicine, but its global research landscape and collaboration patterns remain incompletely mapped.
objectiveTo characterize publication dynamics, cooperative networks, and emerging topics in theranostic research from 2006 to 2024.
methodsArticles and reviews indexed in the Web of Science Core Collection were retrieved for bibliometric analysis. Excel, CiteSpace, VOSviewer, Scimago Graphica, ArcGIS, and the R package bibliometrix were used for quantitative analysis and visualization.
resultsA total of 1801 articles and reviews were included, with a compound annual growth rate of 18.7%. The USA, Germany, and China were the leading producer countries, and the USA-Germany collaboration showed the strongest bilateral link strength. The Helmholtz Association, Memorial Sloan Kettering Cancer Center, and the University of California System were the most productive institutions, while Herrmann K., Wester H.J., and Werner R.A. led individual output. Keyword co-occurrence analysis identified five major themes: prostate-specific membrane antigen (PSMA)-targeted imaging and therapy, somatostatin receptor-based peptide therapy, neuroendocrine tumors, alpha-particle therapy, and fibroblast activation protein-targeted probes. Burst detection showed that fibroblast activation protein, actinium-225, and 177 Lu-PSMA-617 have emerged as recent research hotspots.
conclusionTheranostic research in nuclear medicine has expanded rapidly over the past two decades, with a trans-Atlantic and Asia-Pacific collaborative pattern. Current frontiers are shifting from beta-emitters toward alpha-emitters and tumor-microenvironment-targeted probes. Greater intercontinental cooperation and continued focus on novel radionuclides and under-explored targets may support future innovation and clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.